Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the affinity for D2L, D4.2, and 5-HT2A receptors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 6, 2007, Pages 1570-1574

  Carato, Pascal ^a   Graulich, Amaury ^b   Jensen, Niels ^c   Roth, Bryan L ^c   Liégeois, Jean François ^b  

^a UNIV LILLE   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2A receptors; Antagonist; D4.2 receptors; Schizophrenia

Indexed keywords

2 NAPHTHAMIDE DERIVATIVE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; BENZYL DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4.2 RECEPTOR; DOPAMINE 4.2 RECEPTOR ANTAGONIST; DOPAMINE D2L RECEPTOR; FANANSERIN; N (1 BENZYLPIPERIDIN 4 YL) DERIVATIVE; N (PIPERIDIN 4 YL)NAPHTHAMIDE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PIPERIDINE NAPHTHAMIDE DERIVATIVE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SONEPIPRAZOLE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; DRUG BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; PSYCHOSIS; RECEPTOR AFFINITY; SUBSTITUTION REACTION;

ANIMALS; BENZYL COMPOUNDS; HUMANS; INDICATORS AND REAGENTS; LIGANDS; NAPHTHALENES; PIPERIDINES; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847092174     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.106     Document Type: Article

References (24)

1. Wong A.H.C., and Van Tol H.H.M. Neurosci. Biobehav. Rev. 27 (2003) 269
2. In: Lidow M.S. (Ed). Neurotransmitter Receptors in Actions of Antipsychotic Medications; Pharmacology and Toxicology Series (2000), CRC Press
3. Raviña E., and Masaguer C.F. Curr. Med. Chem. CNS Agents 1 (2001) 43
4. Raggi, M. A. (guest editor) Pharmacological treatment of schizophrenia: Recent antipsychotic drugs and new therapeutic strategies. Curr. Med. Chem. 2004, 11, 267.
5. Roth B.L., Sheffler D.L., and Kroeze W.K. Nat. Rev. Drug Discov. 3 (2004) 353
6. Carato, P.; Graulich, A.; Jensen, N.; Roth, B. L.; Liégeois, J.-F. Bioorg. Med. Chem. Lett., (2007), in press, doi:10.1016/j.bmcl.2006.12.096.
7. Petcher T.J., and Weber H.-P. J. Chem. Soc. Perkin Trans. II (1976) 1415
8. Liégeois J.-F., Eyrolles L., Ellenbroek B.A., Lejeune C., Carato P., Bruhwyler J., Géczy J., Damas J., and Delarge J. J. Med. Chem. 45 (2002) 5136
9. Cheng Y.-C., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
10. Högberg T. Drugs future 16 (1991) 333
11. Arora J., Bordeleau M., Dube L., Jarvie K., Mazzocco L., Peragine J., Tehim A., and Egle I. Biorg. Med. Chem. Lett. 15 (2005) 5253
12. Kapur S., and Seeman P. J. Psychiatry Neurosci. 25 (2000) 161
13. Kapur S., and Seeman P. Am. J. Psychiatry 158 (2001) 360
14. Nyberg S., Eriksson B., Oxenstierna G., Halldin C., and Farde L. Am. J. Psychiatry 156 (1999) 869
15. Kramer M.S., Last B., Getson A., and Reines S.A. Arch. Gen. Psychiatry 54 (1997) 567
16. Corrigan M.H., Gallen C.C., Bonura M.L., Merchant K.M., et al. Biol. Psychiatry 55 (2004) 445
17. Gazi L., Bobirnac I., Danzeisen M., Schupbach E., Bruinvels A.T., Geisse S., Sommer B., Hoyer D., Tricklebank M., and Schoeffter P. Br. J. Pharmacol. 124 (1998) 889
18. Gazi L., Bobirnac I., Danzeisen M., Schupbach E., Langenegger D., Sommer B., Hoyer D., Tricklebank M., and Schoeffter P. Br. J. Pharmacol. 128 (1999) 613
19. Kotecha S.A., Oak J.N., Jackson M.F., Perez Y., Orser B.A., Van Tol H.H.M., and MacDonald J.F. Neuron 35 (2002) 1111
20. Rubinstein M., Cepeda C., Hurst R.S., Flores-Hernandez J., Ariano M.A., Falzone T.L., Kozell L.B., Meshul C.K., Bunzow J.R., Low M.J., Levine M.S., and Grandy D.K. J. Neurosci. 21 (2001) 3756
21. Truffinet P., Tamminga C.A., Fabre L.F., Meltzer H.Y., Riviere M.E., and Papillon-Downey C. Am. J. Psychiatry 156 (1999) 419
22. Tarazi F.I., Zhang K., and Baldessarini R.J. J. Pharmacol. Exp. Ther. 297 (2001) 711
23. Tarazi F.I., Zhang K., and Baldessarini R.J. Psychopharmacology 161 (2002) 263
24. Moran-Gates T., Massari C., Graulich A., Liégeois J.-F., and Tarazi F.I. J. Neurosci. Res. 84 (2006) 675